Monocyte chemoattractant protein-1 serum levels in patients with breast cancer
Monocyte chemoattractant protein-1 serum levels in patients with breast cancer
复制标题
DOI：
10.1159/000077718
复制
发表时间：
2004-01-01
期刊：
影响因子：
--
通讯作者：
Koelbl, H
中科院分区：
文献类型：
--
作者：
Lebrecht, A;Grimm, C;Koelbl, H
趋化因子单核细胞趋化蛋白（MCP）-1被认为参与乳腺癌的发生。我们评估了乳腺癌患者（n = 135），导管原位癌（DCIS）I-III（n = 30），良性乳腺病变（n = 143）和健康女性（n = 27）的MCP-1血清水平。我们确定了MCP-1血清水平作为恶性、浸润前和良性乳腺疾病之间的鉴别标志物以及作为乳腺癌生物学表型的预测标志物的价值。乳腺癌、DCIS I-III、良性乳腺病变和健康女性患者的MCP-1血清水平中位数（范围）分别为200（57-692）pg/ml、194（58-525）pg/ml、174（39-529）pg/ml和175（67-425）pg/ml。患者组间未发现差异。在乳腺癌患者中，MCP-1血清水平升高与晚期肿瘤分期（p = 0.04）和淋巴结受累（p = 0.04）相关。我们不能建立MCP-1作为恶性和良性乳腺疾病之间的鉴别标志物。我们的数据可能表明MCP-1通过促进肿瘤生长和转移扩散影响乳腺癌的发生，从而改变疾病的生物学表型。版权所有（C）2004 S. Karger AG，巴塞尔。
The chemokine monocyte chemoattractant protein (MCP)-1 is thought to be involved in breast carcinogenesis. We evaluated MCP-1 serum levels in patients with breast cancer (n = 135), ductal carcinoma in situ (DCIS) I-III (n = 30), benign breast lesions (n = 143) and in healthy women (n = 27). We determined the value of MCP-1 serum levels as a differentiation marker between malignant, preinvasive and benign breast diseases and as a predictive marker for the biological phenotype of breast carcinoma. Median ( range) MCP-1 serum levels in patients with breast cancer, DCIS I-III, benign breast lesions and healthy women were 200 (57-692) pg/ml, 194 (58-525) pg/ml, 174 (39-529) pg/ml and 175 (67-425) pg/ml, respectively. No differences were ascertained between the patient groups. In patients with breast cancer, increased MCP-1 serum levels were correlated with advanced tumor stage (p = 0.04) and lymph node involvement (p = 0.04). We were not able to establish MCP-1 as a differentiation marker between malignant and benign breast diseases. Our data might indicate that MCP-1 influences breast carcinogenesis by facilitating tumor growth and metastatic spread, thus altering the biological phenotype of the disease. Copyright (C) 2004 S. Karger AG, Basel.